Selective Internal Radiation Combined with Chemotherapy Maintains the Quality of Life in Intrahepatic Cholangiocarcinomas.
Fiche publication
Date publication
novembre 2021
Journal
Current oncology (Toronto, Ont.)
Auteurs
Membres identifiés du Cancéropôle Est :
Pr AYAV Ahmet
Tous les auteurs :
Goislard de Monsabert C, Touchefeu Y, Guiu B, Campillo-Gimenez B, Farges O, Tougeron D, Baumgaertner I, Ayav A, Beuzit L, Pracht M, Lièvre A, Le Sourd S, Boudjema K, Rolland Y, Garin E, Boucher E, Edeline J
Lien Pubmed
Résumé
In the Yttrium-90 Microspheres in Cholangiocarcinoma (MISPHEC) single-arm phase 2 trial, concomitant chemotherapy and selective internal radiotherapy (SIRT) showed antitumor activity as a first-line treatment of unresectable intrahepatic cholangiocarcinomas (ICCs). In this sub-analysis, we aimed to evaluate one of the secondary endpoints, the health-related quality of life (QoL), evaluated with an EORTC QLQ-C30 instrument at the baseline and during treatment.
Mots clés
Yttrium-90, biliary tract cancer, chemotherapy, patient-reported outcomes, radioembolization
Référence
Curr Oncol. 2021 Nov 8;28(6):4530-4541